---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-300218"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:03:39.201699+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax Pharmaceuticals prices $150M public offering of 6.8M shares at $22.00 per share

## Summary
- 6,818,182 shares offered at $22.00 each; underwriters have 30-day option for 1,022,727 additional shares.
- Gross proceeds expected ~$150M ($172.5M if option fully exercised).
- Underwriting led by Goldman Sachs, J.P. Morgan, and Cowen; closing expected December 9, 2022.
- Directors, executive officers, and company subject to 60-day lock-up on share sales without consent.
- Offering made under effective shelf registration statement (File No. 333-254661).

## SEC filing metadata
- accession: 0001193125-22-300218
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312522300218/0001193125-22-300218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312522300218/d420073d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-300218
- JSON: https://secwatch.observer/filing/0001193125-22-300218.json
- Plain text: https://secwatch.observer/filing/0001193125-22-300218.txt

## Key facts
- Material Agreements
  Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC valued at approximately $150.0 million (effective 2022-12-06).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC
  - Value: approximately $150.0 million
  - Effective: 2022-12-06
  source text: On December 6, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 6,818,182 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $22.00 per share (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000119312522300218/0001193125-22-300218-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.